November 5, 2023
Runners will take on the marathon to support CMT research.
If you are interested in participating please email [email protected].
Exciting news for the Charcot-Marie-Tooth (CMT) community! The Hereditary Neuropathy Foundation...
Have questions about HNF’s upcoming CMT Summit + Patient Retreat? We’re here to help! Join Us January 29th from 12:00pm – 1:30pm ET.
Early preclinical research indicates that ALE2 could effectively slow or halt the progression of these debilitating symptoms, offering new hope for patients with these rare forms of CMT.
NMD Pharma Initiates Phase 2 Study of NMD670 in Patients with Charcot-MarieTooth Disease Type 1...
HNF’s Wearable Tech Study Delivers Strong Results for CMT Clinical Trials The Hereditary...
Seeking Participants for a New CMT Clinical Trial (for the US only): A Chance to Help Advance...
Digital Health Technologies for Charcot-Marie-Tooth (CMT) DiseasePatients attending the Clinical...
The INSPIRE trial is a Phase 3 double-blind placebo-controlled registrational study evaluating the effect of once-daily (QD) oral govorestat (AT-007) in 56 patients aged 16-55 with SORD Deficiency in the US and Europe.
HNF is thrilled to announce that we have been accepted to host a 1-hour panel discussion during the Bio International Convention in San Diego, CA, in June 2024.
a patient-initiated at-home genetic testing program, providing faster and more equitable access to critical genetic care for the CMT community and their health care providers.
0 Comments